Jubilant Pharma Singapore is set to sell its entire 25.8% stake in Sofie Biosciences, with the anticipated proceeds reaching up to $139.4 million.
Sofie Biosciences is scheduled to merge with Trilantic North America by June 30.
If the merger transaction falls through, Jubilant Pharma Singapore is poised to receive termination-related fees of up to $7 million from Sofie.
Bringing you the latest updates on finance, economies, stocks, bonds, and more. Stay informed with timely insights.
RBI Reports $56,846 Million Forex Inflows in 2026
WPI Inflation July 2026 Eases to 9.78% From 9.87%
India CPI Inflation Rises to 4.45% in July 2026
F&O Retail Investor Losses: 78.6 Lakh Traders Lost Rs 91,685 Crore in FY26
UPI Charges: 2,366 Crore Transactions, Key Fee Update
RBI Bulletin August 2026: NBFC Credit Grows 14.4%
